331 related articles for article (PubMed ID: 24517491)
1. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.
Abbott-Banner KH; Page CP
Basic Clin Pharmacol Toxicol; 2014 May; 114(5):365-76. PubMed ID: 24517491
[TBL] [Abstract][Full Text] [Related]
2. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.
Banner KH; Press NJ
Br J Pharmacol; 2009 Jul; 157(6):892-906. PubMed ID: 19508401
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
4. PDE inhibitors currently in early clinical trials for the treatment of asthma.
Matera MG; Page C; Cazzola M
Expert Opin Investig Drugs; 2014 Sep; 23(9):1267-75. PubMed ID: 24865624
[TBL] [Abstract][Full Text] [Related]
5. Selective PDE inhibitors as novel treatments for respiratory diseases.
Page CP; Spina D
Curr Opin Pharmacol; 2012 Jun; 12(3):275-86. PubMed ID: 22497841
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
Lipworth BJ
Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
Page CP; Spina D
Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration.
Ochiai K; Takita S; Kojima A; Eiraku T; Iwase K; Kishi T; Ohinata A; Yageta Y; Yasue T; Adams DR; Kohno Y
Bioorg Med Chem Lett; 2013 Jan; 23(1):375-81. PubMed ID: 23200255
[TBL] [Abstract][Full Text] [Related]
9. Superiority of combined phosphodiesterase PDE3/PDE4 inhibition over PDE4 inhibition alone on glucocorticoid- and long-acting β2-adrenoceptor agonist-induced gene expression in human airway epithelial cells.
BinMahfouz H; Borthakur B; Yan D; George T; Giembycz MA; Newton R
Mol Pharmacol; 2015 Jan; 87(1):64-76. PubMed ID: 25324049
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
[TBL] [Abstract][Full Text] [Related]
11. The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways.
Schmidt DT; Watson N; Dent G; Rühlmann E; Branscheid D; Magnussen H; Rabe KF
Br J Pharmacol; 2000 Dec; 131(8):1607-18. PubMed ID: 11139438
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration.
Chapman RW; House A; Richard J; Prelusky D; Lamca J; Wang P; Lundell D; Wu P; Ting PC; Lee JF; Aslanian R; Phillips JE
Eur J Pharmacol; 2010 Sep; 643(2-3):274-81. PubMed ID: 20621091
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase inhibitors. Part 2: design, synthesis, and structure-activity relationships of dual PDE3/4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory and bronchodilatory activity.
Ochiai K; Ando N; Iwase K; Kishi T; Fukuchi K; Ohinata A; Zushi H; Yasue T; Adams DR; Kohno Y
Bioorg Med Chem Lett; 2011 Sep; 21(18):5451-6. PubMed ID: 21764304
[TBL] [Abstract][Full Text] [Related]
14. Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies.
Giembycz MA; Newton R
Handb Exp Pharmacol; 2011; (204):415-46. PubMed ID: 21695651
[TBL] [Abstract][Full Text] [Related]
15. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
Banner KH; Trevethick MA
Trends Pharmacol Sci; 2004 Aug; 25(8):430-6. PubMed ID: 15276712
[TBL] [Abstract][Full Text] [Related]
16. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD.
Cazzola M; Calzetta L; Rogliani P; Matera MG
Expert Opin Investig Drugs; 2019 Oct; 28(10):827-833. PubMed ID: 31474120
[No Abstract] [Full Text] [Related]
17. Phosphodiesterase-4 inhibitor therapy for lung diseases.
Beghè B; Rabe KF; Fabbri LM
Am J Respir Crit Care Med; 2013 Aug; 188(3):271-8. PubMed ID: 23656508
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma.
Al-Sajee D; Yin X; Gauvreau GM
Expert Opin Pharmacother; 2019 Apr; 20(5):609-620. PubMed ID: 30722707
[TBL] [Abstract][Full Text] [Related]
19. Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.
Cazzola M; Page C; Calzetta L; Matera MG
Pharm Pat Anal; 2018 Nov; 7(6):249-257. PubMed ID: 30657422
[TBL] [Abstract][Full Text] [Related]
20. 5-HT4-elicited positive inotropic response is mediated by cAMP and regulated by PDE3 in failing rat and human cardiac ventricles.
Afzal F; Andressen KW; Mørk HK; Aronsen JM; Sjaastad I; Dahl CP; Skomedal T; Levy FO; Osnes JB; Qvigstad E
Br J Pharmacol; 2008 Dec; 155(7):1005-14. PubMed ID: 18846035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
